Avalon Globocare (ALBT)
Market Price (7/4/2026): $0.2844 | Market Cap: $2.5 MilSector: Real Estate | Industry: Real Estate Services
Avalon Globocare (ALBT)
Market Price (7/4/2026): $0.2844Market Cap: $2.5 MilSector: Real EstateIndustry: Real Estate Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -170% | Penny stockMkt Price is 0.3 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is -0.3 Mil Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.5 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -43% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -811% High stock price volatilityVol 12M is 166% Key risksALBT key risks include [1] potential Nasdaq delisting due to non-compliance with equity requirements, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -170% |
| Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is -0.3 Mil |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.5 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -43% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -811% |
| High stock price volatilityVol 12M is 166% |
| Key risksALBT key risks include [1] potential Nasdaq delisting due to non-compliance with equity requirements, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Avalon Globocare (ALBT) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Continued Significant Net Losses and Absence of Revenue. Avalon Globocare reported a net loss of $0.49 per share for its fiscal Q1 2026, which ended March 31, 2026. The company did not disclose any revenue figures for the quarter. As a development-stage biotechnology and AI company, ALBT has consistently shown a lack of recurring revenue, with its annual revenue for fiscal year 2025 being $0.0, and a trailing twelve months (TTM) net income of -$7.53 million as of June 27, 2026. This ongoing unprofitability and lack of top-line growth have fundamentally eroded investor confidence, contributing to the stock's decline.
2. Negative Market Reception to Company News. Despite announcements of strategic collaborations, the market reacted negatively, or with a short-lived positive sentiment, which quickly reversed. For instance, on March 31, 2026, the stock experienced a 6.81% decline following the announcement of a strategic collaboration between Avalon Quantum AI and Caylent. Similarly, on April 21, 2026, the stock dropped 18.09% when Avalon Quantum AI announced teaming up with Caylent and Amazon Web Services for its Agentic AI Platform Development. Furthermore, the Q1 2026 earnings release, around June 3-9, 2026, also saw the stock decline by 5.42% for some investors, reflecting market disappointment over the lack of revenue and ongoing operating losses.
Show more
Avalon Globocare (ALBT) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Continued Significant Net Losses and Absence of Revenue. Avalon Globocare reported a net loss of $0.49 per share for its fiscal Q1 2026, which ended March 31, 2026. The company did not disclose any revenue figures for the quarter. As a development-stage biotechnology and AI company, ALBT has consistently shown a lack of recurring revenue, with its annual revenue for fiscal year 2025 being $0.0, and a trailing twelve months (TTM) net income of -$7.53 million as of June 27, 2026. This ongoing unprofitability and lack of top-line growth have fundamentally eroded investor confidence, contributing to the stock's decline.
2. Negative Market Reception to Company News. Despite announcements of strategic collaborations, the market reacted negatively, or with a short-lived positive sentiment, which quickly reversed. For instance, on March 31, 2026, the stock experienced a 6.81% decline following the announcement of a strategic collaboration between Avalon Quantum AI and Caylent. Similarly, on April 21, 2026, the stock dropped 18.09% when Avalon Quantum AI announced teaming up with Caylent and Amazon Web Services for its Agentic AI Platform Development. Furthermore, the Q1 2026 earnings release, around June 3-9, 2026, also saw the stock decline by 5.42% for some investors, reflecting market disappointment over the lack of revenue and ongoing operating losses.
3. Persistent Uncertainty Regarding Development-Stage Operations and Commercialization. Avalon Globocare's classification as a development-stage company in both cellular therapy and generative AI, without clear commercialization or revenue paths for either segment, has likely contributed to investor apprehension. The capital-intensive nature of advancing preclinical and clinical programs in biotechnology, coupled with the ongoing investments in AI platforms, without corresponding revenue generation, creates significant uncertainty about the company's future financial viability and its ability to achieve profitability.
Show less
Stock Movement Drivers
Fundamental Drivers
The -46.5% change in ALBT stock from 3/31/2026 to 7/4/2026 was primarily driven by a -45.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312026 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.53 | 0.28 | -46.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | -0 | -0 | 0.0% |
| P/S Multiple | -7.4 | -7.3 | -1.1% |
| Shares Outstanding (Mil) | 5 | 9 | -45.8% |
| Cumulative Contribution | -46.5% |
Market Drivers
3/31/2026 to 7/4/2026| Return | Correlation | |
|---|---|---|
| ALBT | -46.9% | |
| Market (SPY) | 14.5% | 2.2% |
| Sector (XLRE) | 9.4% | 6.6% |
Fundamental Drivers
The -76.3% change in ALBT stock from 12/31/2025 to 7/4/2026 was primarily driven by a -57.1% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.20 | 0.28 | -76.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | -0 | -0 | 21.8% |
| P/S Multiple | -17.0 | -7.3 | -57.1% |
| Shares Outstanding (Mil) | 4 | 9 | -54.6% |
| Cumulative Contribution | -76.3% |
Market Drivers
12/31/2025 to 7/4/2026| Return | Correlation | |
|---|---|---|
| ALBT | -76.5% | |
| Market (SPY) | 9.5% | -2.6% |
| Sector (XLRE) | 11.5% | 10.3% |
Fundamental Drivers
The -89.8% change in ALBT stock from 6/30/2025 to 7/4/2026 was primarily driven by a -81.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.78 | 0.28 | -89.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | -0 | -0 | 11.2% |
| P/S Multiple | -14.4 | -7.3 | -49.2% |
| Shares Outstanding (Mil) | 2 | 9 | -81.9% |
| Cumulative Contribution | -89.8% |
Market Drivers
6/30/2025 to 7/4/2026| Return | Correlation | |
|---|---|---|
| ALBT | -89.9% | |
| Market (SPY) | 21.6% | 3.6% |
| Sector (XLRE) | 10.6% | 5.7% |
Fundamental Drivers
The -98.8% change in ALBT stock from 6/30/2023 to 7/4/2026 was primarily driven by a -156.7% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.10 | 0.28 | -98.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | -0 | -129.1% |
| P/S Multiple | 12.8 | -7.3 | -156.7% |
| Shares Outstanding (Mil) | 1 | 9 | -92.6% |
| Cumulative Contribution | -98.8% |
Market Drivers
6/30/2023 to 7/4/2026| Return | Correlation | |
|---|---|---|
| ALBT | -98.8% | |
| Market (SPY) | 74.0% | 3.2% |
| Sector (XLRE) | 30.2% | 1.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALBT Return | -27% | -37% | -91% | -55% | -63% | -76% | -100% |
| Peers Return | 43% | -19% | -6% | 2% | 13% | 11% | 39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| ALBT Win Rate | 33% | 33% | 0% | 33% | 33% | 14% | |
| Peers Win Rate | 72% | 37% | 43% | 50% | 60% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| ALBT Max Drawdown | -48% | -64% | -93% | -88% | -92% | -81% | |
| Peers Max Drawdown | -15% | -38% | -28% | -23% | -27% | -21% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LH, DGX, CRL, BIO, GILD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/2/2026 (YTD)
How Low Can It Go
| Event | ALBT | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -43.4% | -7.8% |
| % Gain to Breakeven | 76.6% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.6% | -33.7% |
| % Gain to Breakeven | 94.6% | 50.9% |
| Time to Breakeven | 41 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -19.5% | -19.2% |
| % Gain to Breakeven | 24.3% | 23.8% |
| Time to Breakeven | 4 days | 105 days |
In The Past
Avalon Globocare's stock fell -43.4% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 76.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ALBT | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -43.4% | -7.8% |
| % Gain to Breakeven | 76.6% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.6% | -33.7% |
| % Gain to Breakeven | 94.6% | 50.9% |
| Time to Breakeven | 41 days | 140 days |
In The Past
Avalon Globocare's stock fell -43.4% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 76.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Avalon Globocare (ALBT)
Avalon GloboCare Corp. (ALBT) operates a diversified business, primarily involved in owning and managing commercial real estate properties across the United States and China. Alongside its real estate ventures, the company has a substantial focus on the healthcare sector, offering a range of medical-related consulting services. This includes specialized advice, executive education, and management support, particularly in the fields of immunotherapy and patient referral services.
A significant portion of Avalon GloboCare's activities is dedicated to biotechnology research and development, aiming to create innovative therapeutic solutions. Its pipeline features leading candidates such as AVA-001, an anti-CD19 CAR-T cell therapy that has completed its first-in-human clinical trial for relapsed/refractory B-cell lymphoblastic leukemia, and AVA-011, another CAR-T therapy in the IND-enabling process. The company is also developing advanced platforms like the RNA-based FASH-CARTM cell therapy, clinical-grade exosome technology (ACTEX), and leverages QTY-code protein design with MIT for diagnostic and therapeutic targets, including a device to treat Cytokine Storm. Furthermore, ALBT is involved in co-developing next-generation, transposon-based CAR-T and CAR-NK therapies and a S-layer vaccine against SARS-CoV-2 through strategic partnerships.
Through its medical consulting arm, Avalon GloboCare provides valuable insights and management services to healthcare entities and professionals. Its primary markets are therefore broad, encompassing commercial real estate tenants, medical institutions, and patients seeking specialized opinions or advanced treatments in oncology and infectious diseases. By developing cutting-edge cell therapies, exosome technologies, and vaccines, ALBT aims to serve critical unmet medical needs within the global healthcare market, ultimately targeting patients suffering from severe conditions and contributing to broader public health initiatives.
AI Analysis | Feedback
Here are a few brief analogies for Avalon Globocare (ALBT):
- An early-stage Moderna for cell therapies and vaccines, also owning real estate.
- An early-stage Johnson & Johnson focused on biotech, also owning real estate.
AI Analysis | Feedback
- Commercial Real Estate Operations: Owning and operating commercial real estate properties in the United States and China.
- Medical Consulting Services: Offering research studies, executive education, expert advisory, and management consulting in areas like immunotherapy and second opinion/referral services.
- AVA-001 (CAR-T Therapy): An anti-CD19 CAR-T cell therapy that has completed its first-in-human clinical trial for relapsed/refractory B-cell lymphoblastic leukemia.
- AVA-011 (CAR-T Therapy): A CAR-T cell therapy undergoing IND-enabling process development after completing pre-clinical studies.
- RNA-based FASH-CARTM Cell Therapy Platform: A proprietary platform for developing RNA-based cell therapies.
- ACTEX (Avalon Clinical-Grade Tissue-Specific Exosome): Developing clinical-grade tissue-specific exosome technology.
- QTY-code Protein Design Technology: Utilizing this technology for developing therapeutic and diagnostic targets, including a hemofiltration device for Cytokine Storm.
- Next-Generation Immune Effector Cell Therapies: Co-developing advanced transposon-based CAR-T, CAR-NK, and other immune effector cell therapeutic modalities.
- S-layer Vaccine: Developing an intranasal or oral S-layer vaccine against SARS-CoV-2 and COVID-19.
- Avalon Cell and Avalon Rehab: Developing specific initiatives or programs under these names.
- Exosome Industry Standardization: Promoting standardization efforts related to the exosome industry.
AI Analysis | Feedback
Avalon Globocare (ALBT) primarily serves other companies, rather than individuals. The provided company description does not explicitly name specific major customer companies but outlines several types of services and properties that would typically cater to a business-to-business (B2B) clientele.
Based on the company's activities, its major customers would fall into the following categories:
- Commercial Real Estate Tenants: Businesses and organizations that lease commercial properties owned and operated by Avalon Globocare in the United States and the People's Republic of China.
- Healthcare, Biotechnology, and Pharmaceutical Companies: These entities would be the primary customers for Avalon Globocare's medical-related consulting services, including research studies, executive education, expert advisory, and management services in areas like immunotherapy. They may also be potential licensees or collaborators for its drug candidates (AVA-001, AVA-011), RNA-based FASH-CARTM cell therapy platform, ACTEX products, QTY-code protein design technology, or the S-layer vaccine once these are commercialized or require further development partnerships.
- Hospitals and Healthcare Institutions: These could be customers for specialized medical services, such as second opinion/referral services (if provided directly to institutions rather than individual patients), or for acquiring developed therapeutic products like CAR-T cell therapies once they are commercialized and available for patient treatment. Potential services like "Avalon Rehab" facilities might also serve other healthcare providers or directly patients referred by institutions.
AI Analysis | Feedback
- Massachusetts Institute of Technology (MIT)
- Arbele Limited
- University of Natural Resources and Life Sciences in Vienna and Austria
AI Analysis | Feedback
Meng Li
Interim Chief Executive Officer, Chief Operating Officer, and Secretary
Meng Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. She served as Managing Director at Maxus/GroupM, a WPP Group company, from 2006 to 2015, where she was responsible for business P&L and corporate management. Before joining Maxus/GroupM, Ms. Li worked for Zenith Media, a Publicis Group company, from 2000 to 2006 as a Senior Manager.
Luisa Ingargiola
Chief Financial Officer and Principal Accounting Officer
Luisa Ingargiola possesses significant experience serving as Chief Financial Officer or Audit Chair for multiple NASDAQ and NYSE companies. She currently serves as Director and Audit Chair for several public companies, including ElectraMeccanica (NASDAQ: SOLO), Dragonfly Energy (NASDAQ: DFLI), and Vision Marine Technologies (NASDAQ: VMAR). From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then Director at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007, she held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola also currently serves as a Board Director and Audit Committee Chair at BioCorRx Inc. She has extensive knowledge of corporate governance, regulatory requirements, and experience in financing and M&A transactions.
Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Wenzhao (Daniel) Lu is a seasoned healthcare entrepreneur with extensive operational experience in China. He has served as Chairman of the Board for the DaoPei Medical Group ("DPMG") since 2010, leading its expansion to include a stem cell bank, private hospitals, hematology laboratories, and a research institute with over 100 partnering hospitals in China. Prior to DPMG, Mr. Lu was the Chief Operating Officer for BioTime Asia Limited, a subsidiary of BioTime, Inc. (NYSE/AMEX: BTX), in 2009.
AI Analysis | Feedback
Key Risks to Avalon GloboCare (ALBT)
- Clinical Trial and Regulatory Failure: Avalon GloboCare is heavily invested in the development of multiple early-stage cell therapies, including CAR-T candidates AVA-001 and AVA-011, an RNA-based FASH-CARTM cell therapy platform, and an S-layer vaccine against SARS-CoV-2. The biotechnology industry, particularly in drug development, is characterized by extremely high failure rates in clinical trials, lengthy and expensive development timelines, and stringent regulatory approval processes. Many drug candidates, especially in early phases, do not advance to market, posing a significant risk to the company's future revenue and success.
- Financial and Liquidity Challenges: Developing multiple biotech candidates requires substantial and sustained capital investment for research and development, clinical trials, and operational expenses. Biotech startups often face high burn rates and significant financing challenges. Avalon GloboCare has demonstrated financial distress, including negative profitability, high volatility, and a need for ongoing capital raises, which highlights a risk to its long-term sustainability and ability to fund its extensive pipeline.
- Real Estate Market and Operational Risks: In addition to its biotechnology focus, Avalon GloboCare owns and operates commercial real estate properties in the United States and the People's Republic of China. This segment exposes the company to risks associated with real estate market fluctuations, potential regulatory changes in both countries, and geopolitical factors. Operational disruptions or downturns in the commercial real estate markets could negatively impact the company's overall financial health and stability.
AI Analysis | Feedback
The widespread adoption of highly effective mRNA and viral vector COVID-19 vaccines developed by major pharmaceutical companies represents a significant emerging threat to Avalon GloboCare's S-layer vaccine candidate against SARS-CoV-2. These established technologies have already captured a substantial global market share and set a high standard for efficacy and safety, potentially limiting the commercial viability and market opportunity for ALBT's vaccine upon its potential entry into a largely saturated market.
AI Analysis | Feedback
Avalon GloboCare: Addressable Market Sizes for Key Products and Services
Avalon GloboCare (NASDAQ: ALBT) is involved in diverse sectors, including commercial real estate, medical consulting, and the development of advanced cell and gene therapies. The addressable markets for its main products and services are substantial and span global and regional scopes.Cell and Gene Therapies
- CAR-T Cell Therapy (AVA-001, AVA-011, RNA-based FASH-CARTM platform, next-generation CAR-T/CAR-NK): The global CAR T-cell therapy market was valued at approximately USD 6.03 billion in 2025 and is projected to reach USD 13.78 billion by 2031, growing at a CAGR of 13.7% from 2026 to 2031. Another estimate places the market at USD 5.82 billion in 2025, expanding to USD 22.36 billion by 2033 with an 18.06% CAGR from 2026 to 2033. The CD19-targeting therapies segment, relevant for AVA-001, held over 65% of the market share in 2025. North America is a dominant region, accounting for 67.7% of the revenue share in 2025.
- Exosome Therapeutics (ACTEX): The global exosome therapeutics market is estimated to be valued at USD 928.93 thousand in 2025 and is predicted to increase to approximately USD 4,020.75 thousand by 2034, growing at a CAGR of 17.68% from 2025 to 2034. Another report projects the global exosome diagnostics and therapeutics market to grow from USD 59 million in 2024 to USD 6,848 million by 2032, at a remarkable CAGR of 81.2%.
QTY-Code Protein Design Technology
- Hemofiltration Device for Cytokine Storm: The global cytokine release syndrome treatment market size was USD 23,614.2 million in 2024 and is expected to boost sales to USD 37,919.24 million by 2031, with a CAGR of 7.00% from 2024 to 2031. Another related market, cytokine-based therapies and inhibitors, was worth USD 150 billion in 2024 and is projected to reach USD 202.66 billion by 2033, growing at a CAGR of 3.4% from 2025 to 2033.
S-layer Vaccine against SARS-CoV-2 (Intranasal/Oral)
- COVID-19 Nasal Vaccine: The global nasal vaccines market is projected to grow from USD 434.21 million in 2025 to USD 623.29 million by 2031, at a 6.21% CAGR. The broader intranasal drug and vaccine delivery market, which includes COVID-19 vaccines, was estimated at USD 70.32 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030.
Medical Related Consulting Services
- Healthcare Consulting Services: The global healthcare consulting services market size was valued at USD 21.34 billion in 2024 and is projected to grow from USD 24.01 billion in 2025 to USD 61.51 billion by 2033, growing at a CAGR of 12.48% during the forecast period. North America held the largest share of this market in 2024.
Commercial Real Estate Properties
- Commercial Real Estate (United States and People's Republic of China): The global commercial real estate market size was valued at USD 6.72 trillion in 2024 and is expected to reach USD 9.11 trillion by 2033, growing at a CAGR of 3.44%.
- United States: The commercial real estate market in the U.S. is a significant contributor to North America's dominance in the global market.
- China: The China commercial real estate market size expanded from USD 855.26 billion in 2025 to USD 909.22 billion in 2026 and is projected to reach USD 1,234.6 billion by 2031, advancing at a 6.31% CAGR between 2026 and 2031.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Avalon GloboCare (ALBT)
Over the next 2-3 years, Avalon GloboCare's (ALBT) future revenue growth is primarily expected to be driven by advancements and commercialization within its biotechnology pipeline. While the company maintains operations in commercial real estate and medical consulting services, its core growth opportunities stem from its innovative therapeutic platforms and product candidates.
-
Advancement and Commercialization of CAR-T/CAR-NK Cell Therapies: A significant driver of future revenue is the progression and eventual commercialization of Avalon GloboCare's Chimeric Antigen Receptor (CAR) T-cell and Natural Killer (NK) cell therapies. Notably, its lead candidate, AVA-011, which utilizes the proprietary FLASH-CAR™ technology, is in development for hematological malignancies such as relapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin lymphoma. The FLASH-CAR™ platform's RNA-based approach aims for more rapid and cost-effective bio-manufacturing, which could facilitate broader patient access and market adoption upon successful clinical development and regulatory approval. Collaborations, including one with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, are focused on advancing clinical development and deploying Avalon's Point-of-Care Modular Autonomous Processing System (PMAPsys™) for on-site manufacturing, further supporting the commercialization pathway.
-
Expansion and Commercialization of Exosome-Based Regenerative Therapeutics (ACTEX™): Avalon GloboCare has initiated the commercialization phase for its clinical-grade tissue-specific exosome (ACTEX™) products, targeting markets such as skincare, scar removal, and hair growth. This move into consumer and aesthetic applications is complemented by the parallel development of clinical programs, including AVA-202 and AVA-203, which are exploring the use of ACTEX™ for angiogenic/orthopedic regeneration and the treatment of fibrotic diseases. These therapeutic advancements represent additional future revenue streams.
-
Development and Potential Commercialization of QTY-code Protein Design Technology: The company's collaboration with Massachusetts Institute of Technology (MIT) on its QTY-code protein design technology is aimed at developing novel therapeutic and diagnostic targets. A key application under development is the AVA-Trap™ platform, designed to combat "cytokine storm" conditions, which can arise in severe infections like COVID-19 and certain cancer therapies. The successful development and market introduction of products derived from this platform could open new revenue avenues for Avalon GloboCare.
-
Development and Potential Commercialization of the S-layer Vaccine: Avalon GloboCare has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna, Austria, to develop an S-layer vaccine. This vaccine candidate is specifically designed for intranasal or oral administration against SARS-CoV-2 and coronavirus that causes COVID-19 disease. Should this vaccine successfully complete development and gain regulatory approval, it could generate significant revenue given the ongoing global demand for effective and accessible infectious disease prevention.
AI Analysis | Feedback
Share Issuance
- Avalon GloboCare secured approximately $3.25 million in gross proceeds from a private placement with institutional investors in February 2026, by selling 6,372,550 shares of common stock (or pre-funded warrants) at $0.51 per share, alongside Series A-1 and A-2 warrants. The company anticipates net proceeds of about $2.8 million to be allocated towards debt repayment and working capital.
- The private placement also included Series A-1 and A-2 warrants, each exercisable for up to 6,372,550 shares at $0.51 per share, which could bring in an additional ~$6.5 million if fully exercised upon stockholder approval.
- In February 2026, Avalon GloboCare issued a promissory note with a principal amount of $233,910 to an accredited investor, generating gross proceeds of $207,000, which included a $26,910 original issue discount. A similar financing deal was made with Vanquish Funding Group for a $233,910 promissory note, sold for $207,000.
- As part of the acquisition of RPM Interactive, Inc. in February 2026, a director received 1,364.840 shares of Series E Non-Voting Convertible Preferred Stock at a stated price of $0 per share, in exchange for 2,600,000 common shares of RPM Interactive, Inc..
Inbound Investments
- In February 2026, Avalon GloboCare successfully completed a private placement with institutional investors, raising approximately $3.25 million in gross proceeds. The net proceeds of about $2.8 million are designated for debt repayment and general corporate and working capital purposes.
- The private placement in February 2026 has the potential to generate up to $9.75 million in total, comprising the initial $3.25 million upfront and an additional $6.5 million if all associated Series A-1 and A-2 warrants are fully exercised.
- Avalon GloboCare entered into financing arrangements in February 2026, including a promissory note for $233,910 (with $207,000 in gross proceeds) with an accredited investor and another identical note with Vanquish Funding Group, both carrying a 12% one-time interest charge and maturing in February 2027.
Outbound Investments
- In December 2025, Avalon GloboCare acquired RPM Interactive, a generative AI software company, in an all-stock transaction.
- The acquisition of RPM Interactive involved the issuance of Series E Non-Voting Convertible Preferred Stock to a director in exchange for common shares of RPM Interactive, Inc..
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Avalon Globocare Earnings Notes | 12/16/2025 | |
| Avalon Globocare Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 223.14 |
| Mkt Cap | 17.5 |
| Rev LTM | 7,653 |
| Op Inc LTM | 1,009 |
| FCF LTM | 859 |
| FCF 3Y Avg | 762 |
| CFO LTM | 1,210 |
| CFO 3Y Avg | 1,119 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.7% |
| Rev Chg 3Y Avg | 1.3% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | 11.9% |
| Op Inc Chg 3Y Avg | -4.4% |
| Op Mgn LTM | 11.1% |
| Op Mgn 3Y Avg | 11.6% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 16.4% |
| CFO/Rev 3Y Avg | 17.2% |
| FCF/Rev LTM | 11.8% |
| FCF/Rev 3Y Avg | 11.3% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Real Property Operations | 1 | 1 | 1 | 1 | 1 |
| Corporate/Other | 0 | 0 | 0 | ||
| Lab Services MSO | 0 | 0 | |||
| Medical related consulting services | 0 | 0 | 0 | ||
| Total | 1 | 1 | 1 | 1 | 1 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Lab Services MSO | 0 | -1 | -9 | ||
| AI generated polishing | -0 | ||||
| Corporate/Other | -18 | -6 | -7 | -12 | -9 |
| Real Property Operations | -1 | -1 | -0 | -0 | |
| Medical related consulting services | -0 | -0 | |||
| Total | -18 | -8 | -17 | -12 | -9 |
| $ Mil | 2024 | 2023 |
|---|---|---|
| Equity method investments, net | 11 | |
| Real Property Operations | 7 | 7 |
| Cash | 3 | |
| Prepaid expense and other current assets | 0 | |
| Rent receivable | 0 | |
| Other non-current assets | 0 | |
| Operating lease right-of-use assets, net | 0 | |
| Corporate/Other | 0 | 0 |
| Receivable from sale of equity method investment | 0 | |
| Receivable from sale of equity method investment, noncurrent portion | 0 | |
| Total | 21 | 7 |
Price Behavior
| Market Price | $0.28 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -90.5% | |
| 50 Days | 200 Days | |
| DMA Price | $1.74 | $2.02 |
| DMA Trend | down | down |
| Distance from DMA | -83.8% | -86.0% |
| 3M | 1YR | |
| Volatility | 98.4% | 167.2% |
| Downside Capture | 345.43 | 238.40 |
| Upside Capture | -78.86 | -78.45 |
| Correlation (SPY) | 0.8% | 3.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.96 | -0.25 | -0.17 | -0.34 | 0.48 | 0.50 |
| Up Beta | 0.76 | -0.72 | -1.35 | 0.25 | -0.07 | -0.69 |
| Down Beta | -1.75 | -2.27 | -2.02 | 1.10 | 1.22 | 1.21 |
| Up Capture | -213% | -56% | -50% | -110% | -36% | -4% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 8 | 15 | 24 | 46 | 100 | 301 |
| Down Capture | 0% | 174% | 284% | 120% | 166% | 109% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 13 | 24 | 37 | 76 | 142 | 425 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -89.2% | 166.8% | -0.69 | - |
| Sector ETF (XLRE) | 9.9% | 14.1% | 0.44 | 5.3% |
| Equity (SPY) | 21.7% | 12.5% | 1.29 | 3.3% |
| Gold (GLD) | 23.1% | 27.7% | 0.73 | 4.7% |
| Commodities (DBC) | 21.3% | 18.6% | 0.90 | -9.0% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 6.1% |
| Bitcoin (BTCUSD) | -42.0% | 42.7% | -1.15 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -69.2% | 198.5% | -0.01 | - |
| Sector ETF (XLRE) | 3.4% | 19.1% | 0.08 | 4.9% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 6.1% |
| Gold (GLD) | 17.9% | 18.3% | 0.79 | 4.5% |
| Commodities (DBC) | 6.9% | 19.5% | 0.25 | -2.3% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 5.3% |
| Bitcoin (BTCUSD) | 12.2% | 53.8% | 0.41 | 4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALBT | |
|---|---|---|---|---|
| ALBT | -47.1% | 178.6% | 0.11 | - |
| Sector ETF (XLRE) | 6.8% | 20.4% | 0.29 | 8.1% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 9.5% |
| Gold (GLD) | 12.1% | 16.1% | 0.61 | 4.6% |
| Commodities (DBC) | 5.7% | 18.0% | 0.25 | 0.1% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 8.8% |
| Bitcoin (BTCUSD) | 59.0% | 66.2% | 0.99 | 5.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/27/2023 | 0.5% | 0.0% | -8.9% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 0.5% | 0.0% | |
| Median Negative | -8.9% | ||
| Max Positive | 0.5% | 0.0% | |
| Max Negative | -8.9% | ||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/27/2023 | 0.5% | 0.0% | -8.9% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 0.5% | 0.0% | |
| Median Negative | -8.9% | ||
| Max Positive | 0.5% | 0.0% | |
| Max Negative | -8.9% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/31/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/31/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/30/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 04/06/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 08/15/2019 | 10-Q |
Industry Resources
| Real Estate Resources |
| The Real Deal |
| Commercial Observer |
| Inman |
| Real Estate Services Resources |
| CBRE Research |
| JLL Trends & Insights |
| Cushman & Wakefield Insights |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.